Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.

Authors:
Husted S; Boersma E.

Journal:
Am J Ther

Publication Year: 2016

DOI:
10.1097/MJT.0000000000000237

PMCID:
PMC5102280

PMID:
25830867

Journal Information

Full Title: Am J Ther

Abbreviation: Am J Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Therapeutics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Steen Husted has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer, and is an advisory board member for AstraZeneca, Bayer, Bristol-Myers Squibb, and Pfizer. Eric Boersma has received honorarium from Sanofi-Aventis, Medtronic, and Servier."

Evidence found in paper:

"Editorial support was provided by Tara N. Miller, PhD (Lyndhurst, NJ) and David Evans, PhD, and Josh Collis (Macclesfield, United Kingdom) at Gardiner-Caldwell Communications; this support was funded by AstraZeneca."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025